SCHEDULE: Morgan Stanley Discloses 7.0% Stake in Jasper Therapeutics

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have reported beneficial ownership of 7.0% of Jasper Therapeutics, Inc.'s voting common stock as of December 31, 2025.

Summary

• Morgan Stanley, along with its wholly-owned subsidiary Morgan Stanley Capital Services LLC, filed a Schedule 13G indicating beneficial ownership in Jasper Therapeutics, Inc.
• As of December 31, 2025, Morgan Stanley beneficially owned an aggregate of 1,969,785 shares of Voting Common Stock, representing 7.0% of the class.
• Morgan Stanley Capital Services LLC, a subsidiary, beneficially owned 1,903,420 shares, representing 6.8% of the class, which is included within Morgan Stanley's aggregate ownership.
• Both entities reported shared voting power and shared dispositive power over their respective holdings.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Jasper Therapeutics, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. The disclosure of a significant stake by a major financial institution like Morgan Stanley can instill investor confidence and potentially attract further institutional interest in Jasper Therapeutics.

Positives

• A significant institutional investor like Morgan Stanley holding a 7.0% stake can be viewed as a positive signal, potentially indicating confidence in Jasper Therapeutics' long-term prospects or strategic value.
• The investment is stated to be in the ordinary course of business, suggesting a standard portfolio allocation rather than an activist position.

Risks

• Intentional misstatements or omissions of fact in the filing constitute federal criminal violations (18 U.S.C. 1001).

Industry Context

StockSavvy.ai notes that institutional ownership disclosures, particularly from major financial firms like Morgan Stanley, are closely watched in the biotechnology and pharmaceutical sectors. Such filings can sometimes precede increased analyst coverage or signal broader institutional interest in a company's pipeline or market position, potentially influencing investor sentiment.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may positively influence investor sentiment and potentially the stock price, signaling validation from a major financial player.

Key Dates

Recommendation

While the disclosure of Morgan Stanley's 7.0% stake is a positive signal, indicating institutional interest, this filing alone does not provide sufficient fundamental business or financial performance data to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further operational updates and financial results from Jasper Therapeutics to make a more informed decision.

Keywords

Jasper Therapeutics, Morgan Stanley, Institutional Ownership, SEC Filing, Schedule 13G, Voting Common Stock, Biotechnology, Investment